| Hans-Günter Meyer-Thompson | Monatliche Neuheiten
USA. FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder
USA. FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder
Today, FDA issued the Federal Register notice, Modifications to Labeling Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence, to encourage the submission of supplemental new drug applications to modify the labeling statements for buprenorphine-containing transmucosal products for the treatment of opioid dependence (BTODs). (FDA – US Food&Drug Administration, USA, 26.12.2024)
https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-changes-labeling-transmucosal-buprenorphine-products-indicated-treat-opioid-use